Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Enliven Therapeutics, Inc. (IMRA)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Dec-31-19Dec-31-18
   10-K10-KS-1/A
Revenues  0.00.08.2
            Revenue growth   -100.0% 
Cost of goods sold  0.00.010.7
Gross profit  0.00.0-2.4
            Gross margin    -29.6%
Selling, general and administrative   [+]9.55.12.4
Research and development  32.219.0 
Other operating expenses    5.8
EBITDA   [+]-41.6-24.1 
            EBITDA margin    -129.6%
Depreciation and amortization  0.10.0 
EBIT   [+]-41.7-24.1-10.7
            EBIT margin    -129.6%
Interest income  0.50.6 
Other income (expense), net   [+]-0.10.1-0.7
Pre-tax income  -41.4-23.5-11.3
Income taxes  0.00.00.0
            Tax rate  0.0%0.0%0.0%
Net income  -41.4-23.5-11.3
            Net margin    -137.6%
   
Basic EPS   [+]($2.97)($33.40)($0.02)
Diluted EPS   [+]($2.97)($33.40)($0.02)
   
Shares outstanding (basic)   [+]13.90.7702.5
Shares outstanding (diluted)   [+]13.90.7702.5
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy